Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Helicobacter pylori infection is the main cause of several gastric diseases including gastritis, peptic ulcer and gastric cancer. Traditional anti-H. pylori treatments fail in up to 20–30% of naive patients requiring intervention. Failed attempts may cause the acquisition of resistance by H. pylori or the selection of resistant/resilient strains, hindering second-line treatments.
One of the most recommended second-line regimens is triple therapy with levofloxacin (LT); however, its efficacy has never been optimal, with an estimated pooled eradication rate of 79%.1 In order to improve these results, Liou and colleagues performed a randomised trial comparing LT with a levofloxacin containing sequential therapy (LS).
The study was …
Contributors AGM drafted the manuscript, and JPG critically reviewed it.
Competing interests AGM has received funds for a scientific oral presentation in one event promoted by Allergan. JPG has received funds to promote research from – and/or has provided advisory and education activities to – Almirall, Allergan, AstraZeneca, Casen Recordati, Nycomed.
Provenance and peer review Commissioned; internally peer reviewed.